Agreements reached under this partnership
Discontinuation- 1
坂田製薬 was required to purchase 600 units of “Kubota Glass®” from the Company by August 2025, for approximately ¥260 million.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
坂田製薬 was required to purchase 600 units of “Kubota Glass®” by August 2025, for approximately ¥260 million.
The Company does not disclose earnings forecasts and will continue to assess the impact of this matter on its financial results.
| Item | Details |
|---|---|
| Name of alliance partner | 坂田製薬株式会社 |
| Alliance partner's business activities | 1. Manufacture, sale, import and export of pharmaceuticals and quasi-drugs 2. Manufacture, sale, import and export of health foods and supplements 3. Sale, import and export of cosmetic containers, packaging and related products 4. Planning, design, sale, import and export of cosmetics 5. Sale of goods and trading 6. Consulting services of all kinds 7. Agency sales of medical equipment, health and beauty devices and related products 8. Agency sales of cosmetic ingredients and related products 9. Domestic and international mail-order sales via the Internet 10. Referral of medical institutions and provision of medical interpretation services for foreign patients seeking treatment in Japan |
| Alliance partner's location | Hannan, Osaka Prefecture |
| Alliance partner's capital | 坂田製薬株式会社: ¥1 million |
| Type of alliance | Discontinuation |
| Details of the alliance | 坂田製薬 was required to purchase 600 units of “Kubota Glass®” from the Company by August 2025, for approximately ¥260 million. |
| Numerical targets under the alliance | 坂田製薬 was required to purchase 600 units of “Kubota Glass®” by August 2025, for approximately ¥260 million. |
| Contract Date | 13 March 2025 |
| Impact on Business Performance | The Company does not disclose earnings forecasts and will continue to assess the impact of this matter on its financial results. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the outlook for specific orders from 坂田製薬 was uncertain, the Company has entered into new agreements with authorized distributors and purchase and sale agreements in the Greater China market, and has also resumed direct sales through e-commerce marketplaces. The Company therefore determined that ending its relationship with 坂田製薬 and focusing on new sales channels was necessary for the rollout of “Kubota Glass®”.